Arca
Skip to content
Tools
Tools

Gamma-secretase

Complex in Homo sapiens that 6 drugs act on.

  • Drugs that act on it: 6
  • Approved: 1
  • In phases 1 to 3: 5
  • Sponsors: 6
  • Genes: 6

Who is on it, and how far along

Every drug ChEMBL records acting on APH1A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved1

  • Nirogacestat

Phase 32

  • Semagacestat
  • Tarenflurbil

Phase 23

  • Avagacestat
  • Begacestat
  • RG-4733

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Myrexis Inc.117%
    • Wyeth is now a wholly owned subsidiary of Pfizer117%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 6 act as: Gamma-secretase inhibitor; the rest name their own mechanism.
    NirogacestatApprovedMerck KGaASmall moleculeInhibitor14
    SemagacestatPhase 3Eli LillySmall moleculeInhibitor0
    TarenflurbilPhase 3Myrexis Inc.Small moleculeModulatorGamma-secretase modulator0
    AvagacestatPhase 2Bristol-Myers SquibbSmall moleculeInhibitor0
    BegacestatPhase 2Wyeth is now a wholly owned subsidiary of PfizerSmall moleculeInhibitor0
    RG-4733Phase 2RocheSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Nirogacestat in Patients With Kaposi SarcomaNirogacestatPhase 2RecruitingAIDS Malignancy ConsortiumApr 20, 2026
    Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)NirogacestatPhase 4RecruitingSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanySep 16, 2025
    A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)NirogacestatPhase 2Active, not recruitingSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanySep 12, 2025
    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMNirogacestatPhase 1 / Phase 2Active, not recruitingGlaxoSmithKlineSep 2, 2025
    Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMNirogacestatPhase 1 / Phase 2Active, not recruitingGlaxoSmithKlineSep 2, 2025
    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMMNirogacestatPhase 1 / Phase 2Active, not recruitingGlaxoSmithKlineJul 25, 2025
    Study of Cryoablation and Nirogacestat for Desmoid TumorNirogacestatPhase 2RecruitingNam BuiJul 17, 2023
    Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyNirogacestatPhase 2RecruitingM.D. Anderson Cancer CenterMay 30, 2023

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094135, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.